EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study

Chan Y Cheah iD, Piers Blombery iD, Amanda Johnston, Joel Wight, Katharine L Lewis, Rory Bennett, Jing Xie, Stella Vlachos, Sally M Hunter, Joyce Gonzales, Sally Binks, John F Seymour

HemaSphere · 2026-06 · 10 (6)

DOI: 10.1002/hem3.70386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 07.06.2026. Verfasst von Chan Y Cheah und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology Sir Charles Gairdner Hospital Perth Australia. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb, Roche, AbbVie.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular lymphoma (FL) is the most common indolent lymphoma. Although chemoimmunotherapy is effective, toxicity remains problematic, and novel treatments are required. We performed a Phase Ib/II study of obinutuzumab, lenalidomide, and venetoclax in patients with treatment‐naïve, high tumor burden, advanced‐stage FL. During induction (6 × 28‐day cycles), patients received obinutuzumab and venetoclax (in four dose levels from 400 mg day [D]1–10 to 800 mg daily) from Cycles 1 to 6 and lenalidomide (20 mg Days 1–21) from Cycles 2 to 6. Patients with complete response (CR) received 2 years maintenance obinutuzumab, while partial responders received 2 years obinutuzumab plus 6 months of venetoclax and lenalidomide. Genomic characterization and measurable residual disease (MRD) monitoring were performed using targeted next‐generation sequencing (NGS) by circulating tumor DNA (ctDNA). Fifty patients were enrolled with a median age 60. No maximum tolerated dose was defined, and the Phase II dose of venetoclax was 800 mg daily. The CR rate and objective response rate were 86% and 92%, respectively. At median follow‐up of 18.3 months, the 2‐year progression‐free survival and overall survival rates were 92% and 100%, respectively. The most common any‐grade adverse events were neutropenia (72%), diarrhea (52%), and upper respiratory infection (48%). Undetectable MRD after one cycle of therapy had a 95% negative predictive value for relapse, while detectable MRD after three cycles of therapy had a 75% positive predictive value. Obinutuzumab, lenalidomide, and venetoclax are active in patients with treatment‐naïve high tumor burden FL; however, myelosuppression impacted deliverability. ctDNA MRD is a promising biomarker in FL.

Autor:innen und Institutionen

  • Department of Haematology Sir Charles Gairdner Hospital Perth Australia.
  • Medical School University of Western Australia Perth Australia.
  • Department of Haematology Peter MacCallum Cancer Centre and the Royal Melbourne Hospital Melbourne Australia.
  • Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Australia.
  • Department of Haematology Westmead Hospital Sydney Australia.
  • Department of Haematology Townsville University Hospital Townsville Australia.

ORCID-Profile: Chan Y Cheah, Piers Blombery

Förderung

  • Bristol-Myers Squibb
  • Roche
  • AbbVie

Zitieren

APA

Cheah, C. Y., Blombery, P., Johnston, A., Wight, J., Lewis, K. L., Bennett, R., Xie, J., Vlachos, S., Hunter, S. M., Gonzales, J., Binks, S., & Seymour, J. F. (2026). Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70386

Vancouver

Cheah CY, Blombery P, Johnston A, Wight J, Lewis KL, Bennett R, et al. Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study. HemaSphere. 2026;10(6). doi:10.1002/hem3.70386

BibTeX
@article{Cheah2026,
  author = {Cheah, Chan Y and Blombery, Piers and Johnston, Amanda and Wight, Joel and Lewis, Katharine L and Bennett, Rory and Xie, Jing and Vlachos, Stella and Hunter, Sally M and Gonzales, Joyce and Binks, Sally and Seymour, John F},
  title = {Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced‐stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {6},
  doi = {10.1002/hem3.70386}
}
Kostenlos starten →